The Big Idea

Cholesterol has a public-relations problem. It gets talked about as if it were a poison sloshing through your bloodstream. It isn’t.

Every cell in your body needs cholesterol to build its outer wall. Your body uses it to make hormones such as estrogen and testosterone, vitamin D, and bile—the greenish fluid your liver sends into the gut to help digest fat.

The problem is not that cholesterol exists. The problem is how many of a specific kind of cholesterol-carrying particle—the kind that can enter and become trapped in artery walls—are traveling through your blood, and how long they stay there before your body clears them out. These are called atherogenic particles.

Because fat and cholesterol do not dissolve in blood, your body packages them into tiny vehicles called lipoproteins—bundles of fat and protein. Think of them as a city transit system: some vehicles run passenger routes carrying cholesterol from stop to stop, some run long-haul freight carrying triglycerides, and a cleanup fleet runs the reverse route home.

Each vehicle has a job, a route, and identifying tags on its surface that tell the body what it is and what to do with it. When there are too many atherogenic vehicles on the road for too many years, some enter the wall of your arteries and become trapped there. That slow buildup is called atherosclerosis. It is the process that quietly leads to heart attacks, strokes, and other vascular disease over decades.

That is the whole story in one paragraph.

The rest of this article—Part 1 of a three-part series—is a tour of the fleet, the tags on each vehicle, and how to read what is actually showing up on your lab report. Parts 2 and 3 will cover what food, exercise, medications, and supplements actually change about the traffic pattern.

The Six Vehicles

Each vehicle carries apolipoproteins on its surface—identifying tags that tell the body what the vehicle is, where it belongs, and what to do with it.

One tag, apoB, is especially useful because it marks nearly every particle capable of contributing to plaque.

Chylomicron — the local shuttle

The pickup out of the gut after a meal. Chylomicrons carry fat from what you just ate into circulation.

Intact chylomicrons are generally too large to enter artery walls. But their smaller leftovers, called chylomicron remnants, can contribute to plaque.

Main tag: apoB-48 — one per particle, the gut-made form of apoB.

Also carries: apoA-I, apoA-II, apoA-IV, apoA-V, apoC-II, apoC-III, and apoE.

VLDL — long-haul freight from the liver

VLDL carries triglycerides made or packaged by the liver to muscle and fat tissue.

As VLDL drops off triglycerides along its route, it shrinks into smaller, cholesterol-rich remnant particles. These remnants can enter artery walls. This is one reason persistently high triglycerides can matter for cardiovascular risk.

Main tag: apoB-100 — one per particle, the liver-made form of apoB.

Also carries: apoC-I, apoC-II, apoC-III, and apoE.

IDL — a VLDL at a fork in the road

IDL is a shrunken VLDL particle. It can return to the liver for clearance or continue along the route and become LDL.

Main tag: apoB-100

Also carries: apoC and apoE. ApoE acts in part as a “return to liver” signal.

LDL — the main passenger route for cholesterol

LDL carries cholesterol through the circulation to cells and tissues. It is the most common plaque-forming particle, but it is not the only one.

LDL, cholesterol-rich remnants, and Lp(a) can all enter and become retained in artery walls. LDL is usually the dominant source of this traffic.

Main tag: apoB-100 — one per particle. This is why an ApoB blood test is such a useful approximation of the number of LDL and other atherogenic vehicles in circulation.

HDL — the return route

HDL participates in moving cholesterol away from tissues and toward the liver.

Its role is biologically complex. A high HDL cholesterol number is not proof that a person is protected from cardiovascular disease, and medications that simply raise HDL cholesterol have not reliably prevented heart attacks or strokes.

Main tag: apoA-I — usually more than one per HDL particle and the defining protein of HDL.

Also carries: apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, and apoE.

Lp(a) — an LDL with an extra fitting

Lp(a), pronounced “L-P-little-a,” is an LDL-like particle with an extra protein attached to it.

Think of it as an LDL bus with an added piece bolted to the back. It carries cholesterol that can enter the artery wall, and its unusual structure may make it especially likely to promote plaque and clotting.

Lp(a) is largely inherited and usually remains fairly stable through adulthood. Most expert groups recommend measuring it at least once in adulthood because an elevated result changes how seriously the rest of the prevention plan should be taken.

Main tag: apoB-100 — the same one found on LDL.

Extra tag: apo(a) — attached to apoB-100 in a 1:1 ratio. Apo(a) helps explain why Lp(a) behaves differently from ordinary LDL.[^1][^2]

The Tag That Matters Most: ApoB

If you take one lab-report word away from this article, make it ApoB.

ApoB is the identifying protein carried by the particles most relevant to plaque: VLDL and its remnants, IDL, LDL, and Lp(a). Chylomicrons carry a related version of apoB, and their remnants can contribute too, but a routine ApoB test is mainly telling you about the atherogenic particles most people are worried about.

What the lab is measuring

Routine ApoB tests do not separately distinguish the liver-made apoB-100 from the gut-made apoB-48.

But under normal conditions—especially after fasting—nearly all of the ApoB measured in blood is apoB-100, the form found on VLDL, IDL, LDL, and Lp(a). That means the ApoB number on your report is, for practical purposes, a close estimate of the number of atherogenic particles most relevant to cardiovascular risk.[^3]

Two lab numbers that sound similar are measuring different things.

LDL cholesterol tells you how much cholesterol is being carried inside LDL vehicles.

ApoB tells you, more nearly, how many atherogenic vehicles are on the road.

A person can have an ordinary-looking LDL cholesterol value but still have a higher-than-expected apoB level because they have many cholesterol-poor LDL or remnant particles. This pattern is more common when triglycerides are elevated, insulin resistance is present, diabetes is present, or LDL-C and apoB do not agree with one another.

In those situations, apoB can provide a clearer estimate of atherogenic particle burden than LDL cholesterol alone.[^3][^4]

ApoB is not the whole risk picture. Blood pressure, diabetes, smoking, family history, chronic kidney disease, Lp(a), physical activity, diet, sleep, and—for selected patients—a coronary artery calcium scan all matter.

But ApoB is one of the most useful single numbers available, and many patients have never had it measured.

If ApoB is not available

Ask for non–HDL cholesterol.

Non–HDL cholesterol is simply total cholesterol minus HDL cholesterol. It measures the cholesterol carried in all of the major apoB-containing particles: VLDL, IDL, LDL, remnants, and Lp(a).

It is inexpensive, appears on nearly every standard lipid panel, and can be calculated from either a fasting or nonfasting sample. It often tracks well with ApoB and is especially useful when ApoB testing is unavailable, although it does not directly tell you the particle count.

The HDL fleet has its own major tag, called apoA-I. A high HDL cholesterol number can sound reassuring, but HDL biology is more complicated than “more is better.” High HDL-C alone is not proof that you are protected.

How to Read Your Lipid Panel

The most common reason a patient tells me their cholesterol is “fine” is that someone glanced at total cholesterol and said the word normal.

Total cholesterol is useful as a starting point, but it is rarely enough to guide a cardiovascular decision on its own. Here is what the report is actually telling you, line by line.

Total cholesterol

This is the sum of the cholesterol carried inside all lipoprotein particles, including LDL, HDL, VLDL, IDL, Lp(a), and remnant particles.

Because HDL cholesterol is included, total cholesterol can sometimes obscure the risk picture. A person with both high HDL-C and high LDL-C may have a total cholesterol level that does not immediately raise concern. Another person with low HDL-C and modest LDL-C may appear “borderline” on total cholesterol alone while having a relatively low apoB or non–HDL-C level.

Use total cholesterol as a starting glance, not as a decision by itself.

LDL cholesterol

LDL cholesterol is the cholesterol carried inside your LDL buses.

On many standard lipid panels, LDL-C is calculated rather than directly measured. Older reports often use the Friedewald equation. Newer Martin-Hopkins or Sampson/NIH equations are generally more accurate, especially when triglycerides are elevated or LDL-C is very low.

If triglycerides are above about 400 mg/dL, a fasting repeat panel is often helpful because the LDL calculation becomes less reliable. In that setting, non–HDL-C and ApoB can be especially useful.

LDL-C remains the number most guidelines are built around and the number many cholesterol medications are titrated against.[^5][^6]

HDL cholesterol

HDL cholesterol is the cholesterol carried inside the HDL cleanup fleet.

Higher HDL-C is associated with lower cardiovascular risk in large populations, but the relationship is not linear all the way up. Very high HDL-C is not necessarily better, and drugs that raise HDL-C have not reliably lowered heart attacks or strokes.

Think of HDL-C primarily as a risk marker and part of the overall metabolic picture—not as a number you should try to push upward with medication.

Triglycerides

Triglycerides are the main form of fat riding inside VLDL freight vehicles and, for a few hours after a meal, inside chylomicrons.

Elevated triglycerides can reflect insulin resistance, excess body weight, diabetes, refined-carbohydrate intake, excess alcohol, hypothyroidism, kidney disease, certain medications, or inherited lipid patterns.

Persistently elevated triglycerides often travel with more triglyceride-rich remnant particles in circulation, and those remnants can enter artery walls. Very high triglycerides also raise the risk of pancreatitis.

A fasting triglyceride below 150 mg/dL is generally considered normal, but the meaning of a result depends on the full metabolic and cardiovascular picture.

Non–HDL cholesterol

Non–HDL cholesterol is your total cholesterol minus your HDL cholesterol.

That one subtraction gives you the total cholesterol carried in all major atherogenic particles: VLDL, IDL, LDL, remnants, and Lp(a).

It is inexpensive, included on almost every standard lipid panel, and useful whether the blood sample was fasting or nonfasting. It often tracks well with ApoB and is especially valuable when ApoB testing is not available, although it does not directly measure particle number.

If ApoB is not available, non–HDL cholesterol is one of the most useful numbers to know.

ApoB

ApoB is not included on a standard lipid panel, so you usually have to ask for it.

It closely estimates the number of circulating atherogenic particles. It does not require fasting and is especially helpful when triglycerides are high, insulin resistance or diabetes is present, or LDL-C and non–HDL-C do not seem to tell the whole story.[^3][^4][^6]

Lp(a)

Lp(a) is not included on a standard lipid panel and must also be requested.

It should be measured at least once in adulthood because it is largely inherited and usually remains fairly stable.

In many expert statements:

• Lp(a) below 30 mg/dL, or below 75 nmol/L, is considered lower risk

• Lp(a) from 30 to 50 mg/dL, or 75 to 125 nmol/L, is considered an intermediate range

• Lp(a) of 50 mg/dL or 125 nmol/L and above is considered high risk

Do not try to convert precisely between mg/dL and nmol/L. The two units are not interchangeable with one fixed formula because Lp(a) particle size varies substantially from person to person.

A high Lp(a) result does not mean disaster. It means your prevention plan—especially LDL-C and ApoB lowering—deserves more attention.[^1][^2][^7][^9]

Ratios

Total-cholesterol-to-HDL and LDL-to-HDL ratios are calculated automatically on many reports.

They can be useful for quick pattern recognition, but they can also hide important problems. A person can have a “great” ratio and still have a genuinely high ApoB or Lp(a).

Ratios are a supplement to the individual numbers, not a replacement for them.

A practical way to read the page

Start with LDL-C, non–HDL-C, and ApoB when it is available.

Then look at triglycerides. They can reveal whether triglyceride-rich lipoproteins and insulin resistance are contributing to the traffic pattern.

Then put all of it into the bigger cardiovascular picture: blood pressure, diabetes or prediabetes, smoking, kidney function, family history, Lp(a), age, sex, exercise, diet, sleep, and—when appropriate—coronary artery calcium.

Total cholesterol and HDL-C add useful context, but neither should dominate the interpretation.

Where Things Go Wrong

Most LDL buses are ultimately cleared by the liver.

The liver does this by putting docking ports on its surface that grab passing LDL particles and pull them in. These docking ports are called LDL receptors. Think of them as depot stations where the fleet gets pulled off the road for the night.

The more LDL-receptor stations the liver has open, the less time an LDL particle spends circulating in your blood. The less time it spends circulating, the less opportunity it has to enter and become trapped in an artery wall.

Anything that reduces the number of working depot stations—genetics, hypothyroidism, kidney disease, certain medications, and, for many people, a diet high in saturated fat—can leave more LDL particles sitting in traffic longer.

Anything that increases clearance—some dietary changes and most cholesterol-lowering medications—can reduce the time those particles spend circulating.

How strongly any individual person responds to these levers varies substantially.

What replaces saturated fat matters. Replacing it with unsaturated fats—such as olive oil, nuts, seeds, avocado, and many fish—usually lowers LDL-C more reliably than replacing it with refined carbohydrate.

Almost every cholesterol-lowering treatment works by pulling one of two levers:

• Run fewer atherogenic vehicles

• Open more LDL-receptor depot stations on the liver

That is the whole map.

What’s Next

You now have the map.

In Part 2, we will walk through what food and exercise actually change about the traffic pattern: which foods change which vehicles, why movement intensity matters, how body composition influences triglycerides and insulin resistance, and where the effects of lifestyle honestly sit next to the effects of medication.

In Part 3, we will cover the medications themselves and take an honest look at the supplements and herbals patients ask about most often—what each one does, what the evidence actually supports, and which ones are usually not worth the money.

Part 2 next Tuesday. Part 3 the Tuesday after.

This article is for patient education. It is not a substitute for individualized medical advice. Cholesterol management should be directed by your physician using validated risk assessment and current guideline-based therapy.

Key Sources

• Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 2019;4(12):1287–1295.

• Soffer DE, et al. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus From the National Lipid Association. Journal of Clinical Lipidology. 2024.[^3][^8]

• Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Valve Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal. 2022.[^9]

• National Lipid Association. A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice. 2024.[^1][^2]

• Feingold KR. Guidelines for the Management of Dyslipidemia. Endotext [Internet]. 2026.[^5]

• Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. 2026;153(17):e1154–e1276.[^4][^6]

[^1]: https://www.lipidjournal.com/article/S1933-2874(24)00033-3/fulltext

[^2]: https://www.lipid.org/resource/a-focused-update-to-the-2019-nla-scientific-statement-on-use-of-lipoproteina-in-clinical-practice/

[^3]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11734832/

[^4]: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423

[^5]: https://www.ncbi.nlm.nih.gov/books/NBK305897/

[^6]: https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia

[^7]: https://www.acc.org/latest-in-cardiology/articles/2023/09/19/10/54/an-update-on-lipoprotein-a

[^8]: https://www.lipidjournal.com/article/S1933-2874(24)00240-X/fulltext

[^9]: https://academic.oup.com/eurheartj/article/43/39/3925/6670882

The short version

• On September 4, Novartis announced that pelacarsen — the first drug ever designed to lower Lp(a), an inherited cardiovascular risk factor — did not reduce heart attacks, strokes, or cardiovascular deaths in its big clinical trial.

• The drug did lower Lp(a) itself. It just didn’t translate that lowering into fewer events.

• The trial, called Lp(a)HORIZON, enrolled 8,323 people who had already had a heart attack, stroke, or serious peripheral artery disease, and who had high Lp(a).

• The trial’s design had real limits. It didn’t measure inflammation. It didn’t image patients’ plaque. It didn’t distinguish between the two very different kinds of Lp(a) particles people can carry. And it may not have run long enough for a lifetime disease to respond.

• Two other Lp(a) drugs, from different companies, are still being studied. Their trials are ongoing.

• For patients: nothing about your care changes today. High Lp(a) is still a risk factor worth knowing. It still means we treat everything else — cholesterol, blood pressure, lifestyle — more aggressively.

• For the science: the Lp(a) story is bruised, not buried.

On September 4, 2026, Novartis announced that pelacarsen, the first drug ever engineered to lower a substance called lipoprotein(a), did not reduce heart attacks, strokes, cardiovascular deaths, or urgent heart procedures in its big Lp(a)HORIZON clinical trial. The drug did what it was designed to do at the chemistry level. It lowered Lp(a) substantially, just as it had in every earlier study. But that lowering did not translate into fewer cardiovascular events over the years the trial ran.

A lot of well-meaning coverage this week has already collapsed the story into “Lp(a) doesn’t matter” or “the Lp(a) hypothesis is dead.” Neither is true. I want to walk you through what HORIZON actually tested, what it didn’t test, and why I think the more interesting part of the story is still ahead of us.

What Lp(a) is, in one paragraph

Lp(a) — pronounced “L P little a” — is a cholesterol-carrying particle in your bloodstream. Everyone makes some. How much you make is set almost entirely by your genes, which is why Lp(a) runs in families and why diet and exercise barely move it. People with high Lp(a) have roughly two to four times the lifetime risk of heart attack and stroke that people with low Lp(a) have. For decades, we had no way to lower it. Pelacarsen was the first drug built specifically to try.

What the HORIZON trial did

HORIZON enrolled 8,323 patients who had already had one of three serious events: a heart attack, an imaging-confirmed stroke, or symptomatic peripheral artery disease (blockages in the leg arteries). Everyone also had a high Lp(a) — at least 70 mg/dL, with a typical enrolled value of about 108 mg/dL.

Each patient was randomly assigned to get either a monthly injection of pelacarsen or a placebo injection. Both groups also stayed on all their usual heart medications — statins, blood pressure pills, and so on. The average patient in the trial already had a well-controlled LDL cholesterol of about 65 mg/dL. Patients were followed for anywhere from four to about six and a half years, depending on when they enrolled.

The trial’s main question was straightforward: would people who got the drug have fewer heart attacks, strokes, cardiovascular deaths, or urgent heart procedures than people who got the placebo? The answer, in the topline data released last week, was no. The two groups came out about the same.

What HORIZON did not measure

This is the part I want you to sit with, because it shapes how much weight the negative result should carry.

HORIZON measured Lp(a) itself, and it collected the usual safety labs — blood counts, kidney function, liver enzymes. That was essentially it on the biology side. It did not measure inflammation markers like hsCRP. It did not measure Lp-PLA2 or oxidized LDL, both of which reflect the inflammatory damage happening in blood vessels. It did not measure the oxidized fatty acids that Lp(a) is thought to carry into the artery wall — even though an earlier, smaller pelacarsen study showed reductions in those markers of 37 to 88 percent.

And HORIZON did not image anyone’s arteries. No serial CT scans. No ultrasounds of the coronaries. No PET scans of vascular inflammation. Nothing to tell us whether pelacarsen actually changed the plaque in patients’ arteries.

Think of it this way. We ran a five-year trial on whether a new drug prevents heart attacks. It didn’t. But we never checked whether the drug did anything to the plaques that cause heart attacks, or to the inflammation that drives them. All we know is that the number on the lab report went down and the clinical events didn’t.

That’s a real gap. Compare it to how the cholesterol drug evolocumab was studied. In the GLAGOV trial, researchers put tiny ultrasound probes inside patients’ coronary arteries before and after treatment. They could actually see the plaque shrinking. In the HUYGENS trial, they used a different high-resolution imaging technique and saw the plaques becoming more stable and less inflamed. By the time evolocumab’s big outcomes trial reported that it prevented events, we already had a chain of evidence linking the drug to the artery wall. HORIZON gives us no such chain.

The units problem, and the isoforms problem

There’s one more thing HORIZON didn’t do that deserves its own section — because it may mean the wrong patients were enrolled.

Lp(a) can be reported in two different units, and those two units measure two different things.

• Milligrams per deciliter (mg/dL) measures the weight of Lp(a) particles in your blood.

• Nanomoles per liter (nmol/L) measures the number of Lp(a) particles in your blood.

Weight and number are not the same thing. Imagine measuring a crowd of people by their total weight versus by counting heads. If some of them are children and some are adults, weight and headcount give you very different answers. The 2022 European Atherosclerosis Society consensus and the 2024 National Lipid Association scientific statement both recommend measuring Lp(a) by particle number, in nmol/L. Particle number is what actually gets stuck in the artery wall. Weight is a rough substitute that can mislead you.

HORIZON enrolled patients based on weight — mg/dL — measured at a central lab. When the design paper mentions nmol/L values, those are just arithmetic conversions, not separate measurements.

Now to the second problem. Lp(a) particles are not all the same size. They have a tail called apo(a) that varies from person to person. Some people inherit small tails. Some inherit large ones. This isn’t just a cosmetic difference:

• People with small tails carry more particles for the same weight — meaning their true Lp(a) count is higher than the weight number suggests.

• People with small tails also seem to have Lp(a) that is more damaging to arteries, particle for particle. A large meta-analysis of 40 studies and 58,000 people found that people with small apo(a) tails had about twice the risk of coronary heart disease compared with people who had large tails.

HORIZON did not measure tail size. It did not sort patients by tail size. It did not analyze small-tail patients separately from large-tail patients. That means the trial mixed together two biologically different groups under a single weight-based cutoff.

Here’s what that could mean in practice. Picture two patients, both enrolled at exactly 90 mg/dL of Lp(a). The one with small tails may have been carrying a much higher number of much more dangerous particles. The one with large tails may have been carrying fewer, less dangerous particles. Both got the same drug at the same dose. Both counted equally in the analysis. If the drug’s benefit depends on how much of the dangerous biology a patient actually has — and there’s every reason to think it does — the small-tail patients may have shown a real benefit that got washed out by the large-tail patients until the average looked like nothing.

This is not a theoretical worry. It is a real reason a negative HORIZON does not close the question of whether pelacarsen works in the patients whose biology it was designed to address.

Why time may still change the answer

Cardiovascular trials are, in a real sense, races between the biology of the drug and the calendar of the trial.

Statins showed their benefit quickly — within a year or two — because they act on both cholesterol and vessel inflammation at the same time. Some other lipid drugs have needed longer.

Lp(a) builds up in artery walls over decades. The people in HORIZON had already accumulated a lifetime of plaque before their qualifying heart attack or stroke. Asking a monthly injection to reverse or even neutralize that burden in four to six years, on top of well-controlled cholesterol, is a demanding test. It’s entirely possible that a five-year curve looked flat while a ten-year curve would separate. It’s also possible that the trial needed younger patients, or patients earlier in their disease, or patients whose cholesterol wasn’t already so aggressively controlled that there was little event risk left to reduce.

Sometimes clinical trial curves overlap for years and then quietly begin to fan apart at the very end. When Novartis presents the full data at the American Heart Association meeting in November, three things will tell us how alive the Lp(a) hypothesis really is.

• Did the “harder” version of the primary endpoint — heart attack, stroke, and cardiovascular death, without the softer “urgent procedure” count — move in favor of the drug?

• Did the sicker patients, with even higher Lp(a) levels above 90 mg/dL, do better on the drug?

• What was the on-treatment Lp(a) level, and how many patients got it down low enough to matter?

What the next generation of trials should do differently

If I could rewrite the Lp(a) research agenda from where we stand today, I would ask four things of the trials that follow.

Build in mechanistic endpoints. Take pictures of the plaques with serial CT or PET imaging in a subset of patients. Measure inflammation and oxidation markers before, during, and after treatment. A negative outcomes trial paired with positive plaque and inflammation data would tell a very different story from a negative outcomes trial with no biology at all.

Enroll on the right measurement. Use particle number (nmol/L), not weight (mg/dL). Sort patients by tail size. Analyze small-tail patients separately from large-tail patients. A trial built on the wrong measurement may weaken its own signal before the first patient is dosed.

Test the hypothesis earlier in the disease. HORIZON studied patients whose arteries were already badly damaged. Two other Lp(a) drugs — olpasiran from Amgen and lepodisiran from Lilly — are still being tested. Both use a newer technology that lowers Lp(a) more deeply and more durably than pelacarsen does. But those trials also enroll patients who have already had events. The truly definitive test would be a trial in high-Lp(a) patients earlier in life, before the first heart attack.

Take follow-up seriously. Event-driven trials that stop after five years are efficient. They are not always long enough for a disease that took fifty years to build.

Where this leaves us in the office

For patients I care for with a high Lp(a), nothing about the HORIZON result changes what I do this month.

Elevated Lp(a) is still an independent, inherited, causal cardiovascular risk factor. Knowing your Lp(a) still matters, because it changes how aggressively we treat everything else — cholesterol, blood pressure, inflammation, the lifestyle levers. A high Lp(a) still means the LDL target should be lower, the blood pressure target tighter, the calcium score more closely watched.

What has changed is our timeline for having a targeted therapy — a drug I can point to and say, “This lowers your Lp(a) and lowers your risk.” That answer is turning out to be more complicated than a single trial can settle. The Lp(a) story is bruised. It is not buried. And the next two trials, with better drugs, longer follow-up, and I hope more careful measurements built into the design, will tell us far more than HORIZON did about what to do with a number we can now measure but still cannot fully treat.

The honest posture, for now, is patience. We have the first real answer. And we have every reason to keep asking the question.

This article is educational and reflects the author’s clinical perspective. It is not medical advice, and it is not a substitute for evaluation and treatment by your own physician. If you have questions about your Lp(a) level or cardiovascular risk, please discuss them with your doctor.

For women-specific cardiovascular content, see the sister publication The Menopause Heart.

Cholesterol has a public-relations problem. This week, on The Integrative Cardiologist, I want to fix it: first with a walking tour of the whole map, then with three Tuesday articles on how food, exercise, medication, and supplements change the traffic.

Cholesterol is often discussed as though it were a poison sloshing through the bloodstream. It is not.

Every cell in the body needs cholesterol to build its outer membrane. Your body uses it to make hormones such as estrogen and testosterone, to produce vitamin D, and to manufacture bile acids — the fluid the liver releases into the intestine to help digest fat.

The problem is not cholesterol’s existence. The problem is exposure: how many cholesterol-carrying particles are circulating, how long they remain in the bloodstream, and whether they enter and become trapped inside artery walls.

Last week’s article on the five calcium scores was about what we can see after years of arterial wear, inflammation, and repair. This article is about the traffic that comes first: the particles in the blood, the factors that make them more likely to accumulate in artery walls, and the levers that can reduce that burden over time.

Where “Good” and “Bad” Cholesterol Came From

Most people arrive at a cholesterol discussion with the same basic vocabulary: LDL is “bad” cholesterol and HDL is “good” cholesterol.

Those labels did not come from marketing. They grew out of decades of observation, including the Framingham Heart Study. In 1948, the US Public Health Service began following roughly 5,200 adults in Framingham, Massachusetts, to understand why heart attacks and strokes occurred in some people and not others. Their children later joined the study. Then their grandchildren. It became one of the most influential long-term records in cardiovascular medicine.

By the 1970s, Framingham investigators had shown that higher LDL cholesterol tracked with greater coronary risk, while higher HDL cholesterol tracked with lower risk. The shorthand stuck.

LDL became the “bad” one. HDL became the “good” one.

But the labels were always incomplete.

LDL is not “bad” because the body made a mistake by producing it. LDL is a normal transport particle. It carries cholesterol through the bloodstream for ordinary biological purposes. HDL participates in cholesterol transport as well, but a high HDL cholesterol number is not a guarantee of protection, and medications that raise HDL-C have not reliably reduced cardiovascular events.

The modern view is more useful.

Atherosclerosis is not passive grease collecting in a pipe. The artery wall is alive. Its inner lining — the endothelium — responds to blood pressure, smoking, diabetes, kidney disease, inflammation, genetics, and decades of metabolic stress.

But the essential first step is that particles carrying ApoB — including LDL, VLDL remnants, IDL, and Lp(a) — enter the artery wall and become retained there. Once trapped, they can be modified, recognized by the immune system, and set off a chronic inflammatory process that becomes plaque.

So LDL is not a moral villain. It is a normal particle that becomes harmful when too many ApoB-containing particles circulate for too many years and repeatedly gain access to the artery wall.

The artery wall matters, and so does the traffic. Atherosclerosis develops when ApoB-containing particles repeatedly enter and remain in an arterial environment made more vulnerable by high blood pressure, smoking, diabetes, kidney disease, inflammation, genetics, and time.

Cholesterol Does Not Travel Freely

Fat and cholesterol do not dissolve well in blood. So the body packages them into tiny particles called lipoproteins — bundles of fat and protein that travel through the circulation.

Some carry fat absorbed from a meal. Some carry triglycerides made by the liver. Some carry cholesterol to tissues. Some participate in moving excess cholesterol back toward the liver.

Each particle has a job, a route, and an identifying protein on its surface — an apolipoprotein — that helps determine where it goes and how the body handles it.

The metaphor has limits, but it is useful to think of these particles as vehicles in a transit system. The key prevention question is not whether any one vehicle is “evil.” It is whether there are too many artery-capable vehicles on the road, for too long.

The Fleet — At a Glance

There are six particles worth knowing.

Chylomicrons are large particles made by the intestine after a meal. They carry dietary fat from the gut into circulation. The intact particles are generally cleared quickly, although their remnants can matter when triglycerides are persistently elevated.

VLDL, or very-low-density lipoprotein, is made by the liver. It carries triglycerides to muscle and fat tissue. As VLDL unloads triglyceride, it becomes smaller and more cholesterol-rich. Those remnant particles can enter the artery wall.

IDL, or intermediate-density lipoprotein, is a short-lived middle stage in the transition from VLDL to LDL. It is also an ApoB-containing particle that can contribute to atherosclerosis.

LDL, or low-density lipoprotein, is the most familiar cholesterol-carrying particle. It delivers cholesterol to tissues throughout the body. When LDL particle burden is too high, it becomes a major driver of plaque formation.

HDL, or high-density lipoprotein, participates in cholesterol transport back toward the liver and has other biologic functions. But a higher HDL cholesterol number does not automatically mean lower cardiovascular risk.

Lp(a) is an LDL-like particle with an additional protein attached. It is largely inherited, can independently raise cardiovascular risk, and is especially prone to retention in the artery wall. It is worth measuring at least once in adulthood.

The Tag That Matters: ApoB

Every VLDL, remnant particle, IDL, LDL particle, and Lp(a) particle carries one ApoB tag on its surface.

That makes ApoB useful. Measuring ApoB gives an estimate of how many potentially artery-entering particles are circulating in your blood.

Your routine lipid panel reports the amount of cholesterol inside LDL particles — your LDL cholesterol, or LDL-C. ApoB answers a different question: how many ApoB-containing particles are actually circulating?

Those are not always the same story.

Two people can have the same LDL cholesterol level but very different ApoB levels. One person may have fewer, cholesterol-rich LDL particles. The other may have many more particles, each carrying less cholesterol. The second person has more opportunities, day after day and year after year, for particles to enter and remain in the artery wall.

This is especially relevant when triglycerides are elevated, insulin resistance is present, diabetes or metabolic syndrome is part of the picture, or LDL-C and the rest of the metabolic story do not seem to match.

LDL cholesterol remains an important number and a central treatment target. But ApoB can add useful information, particularly when the situation is metabolically complicated.

If ApoB is not available, non-HDL cholesterol — total cholesterol minus HDL cholesterol — is present on almost every standard lipid panel and is a helpful, inexpensive surrogate for the cholesterol carried by atherogenic particles.

The practical takeaway is simple: the cholesterol inside each particle matters, but the number of ApoB-containing particles tells us how many chances there are for cholesterol-carrying particles to enter and remain in the artery wall.

Two Main Levers

Most interventions that reduce LDL-related risk work through one or both of two pathways.

First: reduce the number of ApoB-containing particles in circulation. That can involve improving diet quality, reducing excess saturated fat, lowering refined-carbohydrate intake when triglycerides are elevated, losing weight when appropriate, improving insulin sensitivity, and using medications that reduce hepatic cholesterol production or intestinal cholesterol absorption.

Second: improve clearance of LDL from the bloodstream. The liver removes LDL through LDL receptors. Think of them as depot stations. The more receptors available and functioning, the faster LDL can be removed from circulation.

Statins increase LDL-receptor activity. PCSK9-targeting therapies help prevent LDL receptors from being degraded. Other interventions can support the same overall clearance pathway.

The metaphor is imperfect, but it is useful: less atherogenic traffic entering circulation and better traffic removal both reduce lifetime exposure of the artery wall to ApoB-containing particles.

Where Things Go Wrong

Some conditions leave LDL particles circulating longer than they should. Genetics, hypothyroidism, kidney disease, certain medications, and a diet high in saturated fat can all contribute.

Other factors increase the number of triglyceride-rich particles the liver produces. Insulin resistance, diabetes, central weight gain, alcohol excess, and diets high in refined starches and added sugars can raise triglycerides and worsen the overall metabolic pattern.

Then there are inherited conditions that set a high baseline regardless of how well someone eats or exercises. Familial hypercholesterolemia and elevated Lp(a) are two important examples. They are why some people with excellent lifestyles still need medication.

That is not a failure of effort. It is biology.

What Diet and Exercise Can Change

Food does not act on cholesterol through one pathway. Some choices affect cholesterol absorption. Some affect bile recycling. Some influence triglyceride-rich particles, insulin resistance, body weight, or the liver’s ability to clear LDL.

The most reliable dietary foundation is familiar: more vegetables, fruit, beans, lentils, intact whole grains, nuts, seeds, and minimally processed foods; more unsaturated fats from olive oil, nuts, seeds, avocado, and fish; and less reliance on processed meats, sugary drinks, refined carbohydrates, and foods high in saturated fat.

Soluble fiber from oats, beans, psyllium, barley, lentils, apples, berries, chia, and flax can help lower LDL cholesterol. It binds bile acids in the intestine, which encourages the liver to draw on cholesterol and increase LDL-receptor activity. Psyllium and oat beta-glucan are among the most useful and low-risk non-prescription tools for modest LDL lowering.

Replacing saturated fat with unsaturated fat also matters. Olive oil, nuts, seeds, avocado, and fish generally improve LDL-related measures when they replace butter, fatty or processed meats, and other major sources of saturated fat. The substitution is what matters. Adding olive oil to an otherwise highly processed diet is not the same intervention.

Refined carbohydrates and sugary drinks often show up first in the triglyceride number. In people with insulin resistance, diabetes, central weight gain, or a genetic tendency toward high triglycerides, a pattern high in sweet drinks, sweets, refined flour, and heavily processed starches can worsen triglycerides and metabolic health.

Fatty fish is a good protein choice, especially when it replaces processed or fatty meat. For people with very high triglycerides, prescription omega-3 therapy may be appropriate, but a prescription product is not interchangeable with an over-the-counter fish-oil supplement or a couple of servings of salmon each week.

Exercise provides benefits that food alone cannot. Regular movement improves blood pressure, insulin sensitivity, triglyceride clearance, fitness, body composition, sleep, and long-term cardiovascular resilience. A practical goal remains at least 150 minutes a week of moderate-intensity aerobic activity, plus resistance training at least twice weekly.

Fasting is more modestly useful than the internet suggests. A comfortable overnight eating window helps some people reduce late-night eating, improve weight regulation, or improve blood sugar. It is not required for cardiovascular prevention, and whether it improves a lipid panel depends heavily on the quality and quantity of food inside the eating window.

Part 2 will cover these diet, exercise, and fasting questions with specific targets, references, and honest caveats.

What Medications Actually Do

When diet, exercise, and time are not enough — because of genetics, existing plaque, diabetes, chronic kidney disease, familial hypercholesterolemia, or a high lifetime cardiovascular risk — medications provide additional ways to lower ApoB-containing particle burden.

Statins reduce the liver’s own cholesterol production. In response, the liver increases LDL-receptor activity and removes more LDL from the bloodstream. They are the most studied cholesterol-lowering medicines in cardiovascular prevention and reduce heart attack, stroke, and cardiovascular death in appropriately selected patients.

Ezetimibe reduces cholesterol absorption in the intestine. It is often used with a statin when additional LDL lowering is needed or when a person cannot tolerate higher statin doses.

PCSK9-targeting therapies include injectable antibodies given every few weeks and inclisiran, an siRNA therapy given twice yearly after its initial doses. These treatments help preserve LDL receptors and can produce major LDL reductions. They are commonly considered for people with established cardiovascular disease, familial hypercholesterolemia, very high LDL despite maximally tolerated therapy, or selected cases of statin intolerance.

Bempedoic acid reduces cholesterol production upstream from where statins work. It can be particularly useful for people who cannot tolerate statins or need additional LDL lowering.

Icosapent ethyl is prescription-strength purified EPA, a specific omega-3 formulation shown to reduce cardiovascular events in selected high-risk patients with elevated triglycerides. It is not the same as an over-the-counter fish-oil supplement.

Starting medication is not a failure of diet. It is another way to reduce the lifetime traffic that damages arteries.

An Honest Word About Supplements

Patients ask about supplements every day. Some are genuinely useful. Some have modest effects. Some are heavily marketed with claims their evidence does not support.

The short version is this: soluble fiber, especially psyllium and oat beta-glucan, is among the most useful low-risk, non-prescription tools for modest LDL lowering.

Plant sterols may provide a small additional LDL reduction for some people. They can be reasonable as an add-on, but they should not be confused with a proven substitute for statins or other medications that reduce cardiovascular events.

Red yeast rice deserves special caution. It may work because some products contain monacolin K, a compound chemically identical to lovastatin. In other words, it can act like a statin because it is, pharmacologically, a statin exposure. Product contents can vary substantially. It can cause muscle symptoms, liver-enzyme abnormalities, medication interactions, and other adverse effects. It deserves medical supervision, not a “natural” free pass.

Berberine is promising but inconsistent across preparations and studies. It can affect blood sugar, may modestly improve lipid measures in some people, and has real potential for medication interactions and gastrointestinal side effects. It is not a substitute for guideline-based therapy when medication is indicated.

Aged garlic extract may have modest effects in some studies, but the results are mixed. Curcumin remains an interesting compound for research, but it should not be presented as a proven cardiovascular-prevention supplement. Niacin, once widely promoted for HDL and cholesterol management, did not improve cardiovascular outcomes when added to statin treatment in major modern trials and produced meaningful side effects.

The central rule for the supplement aisle is simple: a product that changes a laboratory number is not automatically proven to prevent a heart attack or stroke.

Part 3 will cover ten commonly discussed supplements — what they may do, what they probably do not do, and which ones I would generally skip.

What This Means for Your Next Visit

If you take nothing else from this Sunday overview, take these six questions into your next appointment:

• Ask whether ApoB would add useful information to your lipid assessment, especially if triglycerides are elevated or you have insulin resistance, diabetes, metabolic syndrome, or a mismatch between LDL-C and your overall risk picture.

• Ask for an Lp(a) measurement at least once in adulthood if you have never had one.

• Ask whether high-sensitivity CRP, or hsCRP, would add useful information in your case. It is a nonspecific marker of systemic inflammation, not a direct measurement of inflammation inside your arteries, but a persistently elevated level can sometimes help refine cardiovascular risk.

• Take blood pressure, waist circumference, physical activity, sleep, blood sugar, and smoking status as seriously as the cholesterol numbers. They are cardiovascular numbers too.

• If the decision about medication is unclear, ask whether a coronary artery calcium score would help. CAC is most useful as a decision tool when risk is uncertain — not as routine testing for everyone.

• Ask directly whether your current numbers warrant medication and, if you already take medication, whether the dose and treatment plan fit your actual risk rather than simply the laboratory reference range.

The question is not simply, “Is my LDL normal?”

A better question is: “Given my full risk profile, is my lifetime exposure to ApoB-containing particles low enough to protect my arteries over the next twenty to thirty years?”

That is the central framework for this series.

What’s Coming This Week

Tuesday 9/8/26 — Part 1: The Framework
A closer look at the six particles, the ApoB tag, and how to read your own lipid panel through this map. Where each number comes from, what it tells you, and what it cannot tell you.

Tuesday 9/15/26— Part 2: How Diet, Fasting, and Exercise Change the Traffic
Which foods affect which parts of the lipid system. Why exercise matters beyond the scale. Where fasting can help, and where it is oversold.

Tuesday 9/22/26 — Part 3: Medications and Supplements — What the Evidence Actually Supports
A practical tour of the prescriptions that reduce heart attack and stroke risk, plus an evidence-based look at the ten supplements patients ask about most: useful options, modest add-ons, and products I would generally avoid.

If a term in today’s overview raised a question you want answered in greater depth, one of the next three articles will probably address it. If not, reply to the Tuesday emails. Your questions will help shape future posts.

This article is for patient education. It is not a substitute for individualized medical advice. Cholesterol management should be directed by your clinician using validated risk assessment and current guideline-based therapy. Do not start, stop, or change any medication or supplement without discussing it with your healthcare professional.

Sources

• Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. Lancet. 2013.

• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High Density Lipoprotein as a Protective Factor Against Coronary Heart Disease: The Framingham Study. American Journal of Medicine. 1977.

• Ross R. Atherosclerosis — An Inflammatory Disease. New England Journal of Medicine. 1999.

• Libby P. Inflammation and the Pathogenesis of Atherosclerosis. Vascular Pharmacology. 2024.

• Glavinovic T, et al. Physiological Bases for the Superiority of Apolipoprotein B Over LDL Cholesterol and Non-HDL Cholesterol as a Marker of Cardiovascular Risk. Journal of the American Heart Association. 2022.

• National Lipid Association. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus.

• Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019.

• Boden WE, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine. 2011.

• Landray MJ, et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine. 2014.

• Piercy KL, et al. The Physical Activity Guidelines for Americans. JAMA. 2018.

• National Center for Complementary and Integrative Health (NIH). Red Yeast Rice.

Before the ultrasound, before the calcium scan, before the lab draw, physicians made their living from inspection. Long before I could order a coronary CT, the cardiologists who trained me were reading the patient at the door: the earlobe, the eyelid, the ring around the iris, the color of the skin at the nape of the neck. Half of the finding was already in the room by the time the stethoscope came out.

Most of those clues live above the collarbone, which means your bathroom mirror sees them before I do. What follows are five things I look at on a patient’s face, and, roughly in the order you would notice them washing up in the morning, five things you can look at on yours.

None of the signs below is proof of heart disease. None of them is enough, by itself, to change your care. They are flags.

Think of the real drivers of cardiovascular risk as ingredients in a recipe. The familiar ones (high blood pressure, high cholesterol, smoking, diabetes, insulin resistance, a sedentary lifestyle, a poor diet, a strong family history of early heart disease, and chronic low-grade inflammation, which we sometimes measure with a high-sensitivity CRP test) are the ingredients that, when they collect in the same bowl, eventually bake the cake we are trying to avoid: a heart attack or a stroke. No single ingredient bakes the cake. The more of them accumulate in one person, the closer that person gets.

The five findings below are not the ingredients. They are visible clues on the outside of the bowl that an ingredient may already be inside. Early corneal arcus points at a lipid disorder. Acanthosis nigricans points at insulin resistance. Xanthelasma may point at how the body handles cholesterol at the tissue level. Persistently bleeding gums point at a chronic inflammatory state. A diagonal earlobe crease points at something we are still trying to understand.

None is a diagnosis. None is a reason to go request a specific test. Each is, at most, a reason to book a check-up and let your primary care physician decide what, if anything, is worth looking into.

Patient stories in this piece are composites; identifying details have been changed. The accompanying images were generated with AI software to illustrate composite clinical findings rather than photograph any specific patient.

1. A diagonal crease across your earlobe

The first time I noticed Frank’s sign on my own was in a 62-year-old accountant who had come in to the clinic for a routine heart checkup. No chest pain, walked three miles a day, took no medications. His earlobes carried a shallow, symmetric diagonal wrinkle I recognized only because a senior colleague had drawn it on a napkin for me years earlier during my training. The calcium score I later ordered from his age, family history, and lipids, not from the earlobe, came back elevated.

A diagonal crease running from the opening of the ear canal down and back toward the outer edge of the earlobe.

Turn your head slightly and look at your earlobe. A diagonal wrinkle that runs from the opening of the ear canal at about a 45-degree angle down and back toward the outer edge of the lobe is called Frank’s sign, after Sanders T. Frank, the American physician who first described it in 1973.

When you pool 12 studies and 5,000 people, people with the crease had roughly four-fold higher odds of coronary artery disease than people without it. That number is loud. It comes largely from patients who were already inside a cardiology setting (hospitals, catheterization labs, chest-pain clinics), where the prior probability of disease is high before the earlobe is even looked at.

Ask the same question in the general population and the answer shrinks. The Copenhagen City Heart Study followed nearly 11,000 adults for an average of 23 years. After adjusting for age, sex, cholesterol, blood pressure, diabetes, smoking, and family history, the crease was associated with about a 9 percent increase in ischemic-heart-disease risk. A separate diagnostic-accuracy review reached the same practical conclusion: the crease shifts the probability only slightly and should not, by itself, change what tests a person gets.

Bilateral creases, one on each ear, appear to carry a stronger association than a one-sided crease, at least in patients referred for coronary angiography.

Why would a wrinkle on the ear correlate with heart disease at all? No one is entirely sure. The leading hypothesis is that the earlobe sits at the far end of the ear’s blood supply, a small fatty flap with comparatively sparse vasculature and physiologically lower oxygen levels (autopsy series). That could make it prone to age-related, low-grade injury of the same type that is quietly damaging small vessels elsewhere in the body. Small biopsy studies have reported fragmentation of elastic fibers and thickening of small-vessel walls under creased earlobe skin, and one autopsy series found microscopic fibrosis and nerve changes at the base of the crease (Elliott et al.; autopsy series). These are real observations. They do not prove that ear-vessel injury and coronary injury are the same process, and part of what looks like small-vessel change on histology may simply be ordinary sun-related skin aging. Shared effects of aging, cardiometabolic risk factors, and connective-tissue biology are all still on the table.

The crease is not a diagnostic test. Plenty of people with it have clean coronaries, and plenty of people without it still develop heart disease. It is a flag on the door, not a note from the doctor. If you see one, especially on both ears, book the check-up you have been postponing.

2. Yellow plaques on your eyelids

A patient of mine once found her own xanthelasma in the visor mirror of her car, on the drive home from a lipid panel her physician had called normal. She sent me a photograph the next morning. Her LDL was in range; her HDL was not. The plaque did not send her to imaging by itself. It joined her family history, her HDL, and her age in a conversation that eventually did.

Xanthelasma: soft, yellowish plaques on the eyelids, most often near the inner corner by the bridge of the nose.

Xanthelasma are soft, yellowish, slightly raised patches on the upper or lower eyelids, most often near the inner corner by the bridge of the nose. Up close they look almost like a smear of yellow wax under the skin, which is close to what they are: macrophages that have swallowed cholesterol and settled where the skin is thinnest.

Their significance is easy to underestimate, because about half of people with xanthelasma do not have obviously high cholesterol on a routine lipid panel, though many still have subtler abnormalities, most often a low HDL. And yet the Copenhagen City Heart Study, nearly 13,000 people followed for up to 33 years, found that xanthelasma independently predicted heart attack, ischemic heart disease, and death, even after adjusting for cholesterol and triglycerides. The same study found no independent association with ischemic stroke.

My working interpretation is that xanthelasma may reflect something about how a particular person handles cholesterol at the tissue level that a standard lipid panel does not capture. Residual confounding and other pathways cannot be excluded, and this is still an area of active work.

One practical note. Cosmetic removal clears the plaque. It should not be assumed to change cardiovascular risk. The dermatologist takes the wax off the eyelid. Your primary care physician deals with what put it there.

If you see one, bring it up at your next visit, not your next cosmetic consult.

3. A pale ring around the colored part of your eye

A 38-year-old marathon runner sat across from me last winter and asked why his eyes looked older than his face. He had a soft grayish ring at the outer edge of each iris. His father had died of a heart attack at 47. His LDL, when we checked it, was 244. On the criteria we use for familial hypercholesterolemia, he scored as definite. Which meant the more important conversation was not really about him. It was about his brother, his sister, and his two children, who all needed a lipid panel of their own.

Corneal arcus: a grayish ring at the outer edge of the iris, formed by lipid depositing in the peripheral cornea.

Lean in close and look at the outer edge of the iris where it meets the white of the eye. A grayish-white, blue-white, or yellowish ring at that border is called corneal arcus. It is lipid, depositing in the peripheral cornea.

The interpretation depends almost entirely on age. In older adults, corneal arcus is largely an age-related change, and once you account for age the Framingham cohort found that arcus, by itself, no longer predicts cardiovascular disease.

Corneal arcus before age 45 is a different matter. It is a recognized criterion in the Dutch Lipid Clinic Network scoring system for familial hypercholesterolemia, an inherited condition where lifetime cholesterol exposure runs high from a young age and where treating early meaningfully changes outcomes. If a first-degree relative has been diagnosed, cascade screening (a lipid panel on parents, siblings, and children) is the highest-yield thing that finding can do. Arcus in anyone under 50 is still worth mentioning to your doctor as a possible clue to a lipid disorder, even outside the formal FH criteria.

One more thing to know. If the ring shows up on only one eye, that asymmetry has been associated with narrowing of the carotid artery on the opposite side. The mechanism is counterintuitive: the narrowed artery sits on the side of the eye without the ring, because reduced flow on that side keeps the lipid from depositing there. It is rare. It is worth mentioning specifically.

Under 50 and see either pattern? Treat it the way you would treat a xanthelasma. Book the visit.

4. Dark, velvety skin at the nape of your neck

A teenage patient once told me his mother kept scrubbing the back of his neck because she thought he was not showering. He was. The skin at the nape was velvety, brownish, and would not come off. His labs showed the picture of insulin resistance, and his BMI was in a range no one had thought to worry about. He was the exception, and that is part of why I remember him: most of the acanthosis I see is in people carrying extra weight. His story is the reminder that the skin finding can arrive first.

Acanthosis nigricans at the nape of the neck, with several small skin tags along the same crease.

Turn a bit and look at the back of your neck, at the folds under your jaw, and in your armpits. Brownish-to-black, thickened, velvety patches, the kind of finish that can make skin look dirty even after you have scrubbed it, are acanthosis nigricans. Small, soft, stalk-like skin tags (acrochordons) often keep them company along the same folds. On darker skin the color contrast is subtler, so look for the change in texture rather than the change in shade.

Both are visible clues to insulin resistance, the state in which the body has to make more and more insulin to keep blood sugar in range. Acanthosis nigricans is closely tied to hyperinsulinemia, and dermatologists have described it as a clinical stand-in for laboratory-measured insulin resistance, though the same review is careful to note that acanthosis is neither necessary nor sufficient for the diagnosis and that obesity itself is a stronger determinant. Skin tags are also nonspecific and occur commonly in people without any metabolic issue at all.

Insulin resistance is one of the central pathways linking abdominal weight gain to high blood pressure, fatty liver, unfavorable cholesterol patterns, and type 2 diabetes, most of which are relevant to the heart. In women, acanthosis nigricans can also be part of the picture of polycystic ovary syndrome.

One different scenario, worth naming plainly. Acanthosis that appears rapidly, spreads extensively, or is itchy in an adult can, rarely, be a paraneoplastic sign of an internal cancer, most commonly of the stomach or another abdominal organ. That pattern needs a same-week appointment, not a routine one.

In every version of this story, the destination is the same doctor. Only the timeline changes.

5. Your gums when you brush

The last thing most of us do at the mirror is brush our teeth, and the sink gives an honest verdict. Occasional bleeding after a change in floss technique is common and reversible. Persistent bleeding on brushing, gums that have receded up the tooth, and teeth that feel loose are the visible face of periodontal disease.

Inflamed, bleeding gum tissue at the margin between gum and tooth: the visible face of periodontal disease.

Of all five signs in this article, this is the one where it is easiest to overstate the case. Let me walk up the ladder honestly and stop where the evidence stops.

What is reasonably well established is that people with periodontitis have, on average, modestly higher levels of inflammatory markers like C-reactive protein and interleukin-6 than people with healthy gums. Treating gum disease is associated with a short-term reduction in CRP that is variable across trials, appears to fade by a year, and has not been shown in patients who already have cardiovascular disease. In the Tonetti randomized trial, intensive periodontal treatment improved endothelial function (how well small blood vessels relax and open) for several months.

What is not established is the final rung: that treating gums prevents heart attacks and strokes. No randomized trial has yet shown a reduction in hard cardiovascular events after periodontal treatment. Mendelian randomization studies, a genetic technique that can strengthen causal inference, have on the whole not supported a causal relationship between periodontitis and coronary disease or stroke. The American Heart Association’s 2025 update is explicit: gum disease is an associated risk marker for heart attack, stroke, atrial fibrillation, and heart failure, but a direct cause-and-effect relationship has not been proven, and shared drivers (smoking, diabetes, chronic inflammation, socioeconomic circumstances) may explain part of the overlap.

So where does that leave the mirror? Persistently bleeding gums are a visible clue that a chronic, low-grade inflammatory state may be present, and that some of the same drivers that damage gum tissue may also be acting on artery walls elsewhere. They are not proof of heart disease. Treating them is not a proven way to prevent it. But they are not “normal” either, and they belong on the list of reasons to see a dentist promptly and to mention the finding at your next primary care visit.

One safety note. Bleeding gums that are new, heavy, or accompanied by easy bruising, nosebleeds, or bleeding from other sites, especially in a patient on warfarin, a direct oral anticoagulant, or a strong antiplatelet regimen after a stent, need a same-week appointment rather than a routine one.

How to use these five

None of these signs, by itself, causes a heart attack. None of them is a causal risk factor, meaning something you could change and thereby change your risk. Each is a flag: a visible clue that a real risk factor may already be in the bowl.

• A diagonal earlobe crease. The accumulated wear-and-tear of ordinary cardiovascular risk factors may already be at work. The underlying mechanism is still debated.

• A xanthelasma. The body may be handling cholesterol in a way a routine lipid panel does not fully capture.

• Corneal arcus before 45. A formal criterion for familial hypercholesterolemia. Arcus in anyone under 50 is a broader clue worth mentioning.

• Acanthosis nigricans at the nape. A well-recognized clue to insulin resistance, with the caveats above.

• Persistently bleeding gums. A clue to chronic low-grade inflammation, one of the modifiable contributors to cardiovascular risk over time, though treating the gums has not been shown to lower cardiac risk.

The real ingredients (high blood pressure, an unfavorable cholesterol pattern, smoking, diabetes, insulin resistance, a sedentary lifestyle, a poor diet, a strong family history of early heart disease, and chronic low-grade inflammation) are what actually bake the cake when enough of them collect in the same bowl. The five findings in this article are not enough, on their own, to bake anything.

They are the flags you can see for free every morning without a blood draw or a scan. Each one points to an ingredient a check-up can look for.

If you notice one, especially corneal arcus before 50, a xanthelasma at any age, new acanthosis nigricans, or long-standing bleeding gums, that is a legitimate reason to book a visit with your primary care physician, who can weigh it against the rest of your history and decide what, if anything, is worth testing.

The mirror does not diagnose anything. What it can do is show you a flag, and give you the chance to have that conversation a year earlier than you otherwise would.

In prevention, a year is often the whole margin.

If cardiovascular risk for women in and around menopause is what you came here for, that conversation lives at our sister publication, The Menopause Heart.

The Integrative Cardiologist is a free patient-education publication and is not a substitute for individualized medical advice. Nothing here constitutes a diagnosis or a recommendation to start, stop, or change any medication or treatment. If you notice a new or worsening physical finding, please speak with your own physician.

By Sameer Azhak, MD, FACC

At 58 Robert was 4 years away from the age his dad died. Calcium score 340, LDL 165, he came in to be seen. I could feel the tension when I walked in to greet him. He still had his coat on. The printout was folded into quarters in his shirt pocket, and he had folded and unfolded it enough times that the crease had gone soft.

He had read the number to his wife over the phone from the parking lot of the imaging center. By the time he sat down across from me he had already done what most people do, which is search the number, land on a survival curve built from a population he has never met, and decide that 340 is a sentence with a date attached to it.

It is not. And the reason it is not is the whole subject of this letter. Robert is not one of the five patients I am going to walk you through today. He is every patient who has ever come into my office holding one of these reports.

I have been ordering coronary calcium scans for most of my career, and I have watched the same test do two different jobs depending on what the patient walks out of the office holding. Without context, the number is what they think about at two in the morning. With a plan around it, the same number can be the most useful piece of information they have ever received about their own body. Same scan, same score, different interpretation.

So let me do here what I do in the room. Five patients from my practice. Five scores. Five different plans. The patients are composites, with identifying details changed and the physiology kept honest.

What the number in Robert’s pocket actually counts

One paragraph on the picture itself, because it changes how the score lands. Think of arterial plaque the way you think about spackle. When the wall of an artery gets injured, the body patches it. Early on, that patch is wet spackle — soft, lipid-rich, unfinished, easy to knock loose. Over years, the body cures the patch. Calcium moves in, the patch hardens, and what was soft becomes stone. What the scanner sees is a repair reaching completion.

The calcium scan photographs the cured spackle. The scanner counts every coronary speck at 130 Hounsfield units or higher, multiplies the area of each speck by a weighting factor tied to its peak density, and adds it all up. That sum is the Agatston score, and the density weighting runs from 1 for a lesion in the 130 to 199 range up to 4 for anything 400 and above. The scan takes about ten seconds of breath-hold, uses no contrast, and delivers roughly the radiation of a mammogram.

So the number in Robert’s shirt pocket is a count of finished repairs. Hold that. Everything below follows from it.

Frank at 1,247, and the stress test that lied

Frank is 78. Retired postal supervisor, widowed two years, lives alone in the house he raised his kids in. His score came back at 1,247. He had walked six minutes on a Bruce protocol treadmill test the week before, and the nuclear images from that study had been read as normal. He came to see me because he had noticed, over the previous month, that walking the empty garbage cans back up to the street left him more winded than it used to. Not chest pain. Just a fatigue at the end of the driveway that hadn’t been there in June.

Six minutes on a Bruce is a short study, and a normal perfusion scan in a 78-year-old with a calcium score above 1,000 is a combination I do not take at face value. Nuclear perfusion imaging compares blood flow across territories of the heart. It looks for a relative defect — one wall darker than its neighbor. When all three coronary arteries are narrowed to roughly the same degree, every wall dims together, the relative comparison finds no defect, and the study reads out as normal. Cardiologists call this balanced ischemia. It is a well-documented false-negative pattern in triple-vessel disease, and it is exactly the kind of miss a very high calcium score is designed to catch.

A Journal of Nuclear Medicine study looked at exactly this scenario — patients with normal SPECT imaging and a calcium score above 1,000 who went on to cardiac catheterization. The added diagnostic yield was substantial, and the mechanism was not always balanced ischemia in three-vessel disease. Sometimes a single vessel was severely narrowed and the nuclear study had simply missed it. For me, a normal stress test in a patient with a 1,247 is not an ending. It is the next question.

I laid the two paths out for Frank in the office. One was a CT angiogram, non-invasive, contrast in a peripheral vein, a definitive answer for whether obstructive disease was there. The other was a diagnostic catheterization, invasive, definitive for both anatomy and treatment in the same setting if a lesion needed a fix. He chose the cath. He wanted the answer and, if there was a fix, he wanted it in the same visit. He had three-vessel disease. He is now three months out from bypass surgery and back to walking the trash cans up the driveway without stopping.

The calcium score and the stress test ask different questions. The stress test asks whether the heart muscle is short of blood right now. The calcium score asks how much repair work is written into the walls of the arteries. When the two disagree, the calcium score is often the one telling you the truth.

Tony walked thirteen minutes

Tony is 65. Two hundred and thirty pounds at five feet nine, built like a man who has been in a gym six days a week for forty years. Retired firefighter, part-time strength coach. He has been on testosterone for twelve years and used anabolic steroids in his forties. His calcium score came back at 1,159, which arrived in his inbox at 6 AM and cost him his morning.

The number, in isolation, put him in the same statistical bin as Frank. In the MESA analysis, a score of 1,000 or higher carried a 4.7-fold adjusted risk of cardiovascular events compared with a zero. Treated from the number alone, Tony would be on maximum medical therapy, a low-dose aspirin conversation, and a rescan schedule.

Then Tony walked thirteen minutes on the same Bruce protocol Frank had done six minutes of. Thirteen minutes on a Bruce is a full-length study. The nuclear imaging was normal. No perfusion defect, no post-stress wall motion change, ejection fraction preserved through recovery. In most practices Tony’s evaluation would have stopped there. I sat down with him and laid out the same two paths I had offered Frank. He knew his exercise capacity, and he knew that a 1,159 with a decade of steroid history was not a number he was going to sleep on. He chose the cath. The coronaries showed mild luminal irregularities. Diffuse calcification of the arterial wall. No narrowing that would justify a stent, no lesion that would justify a bypass.

Two facts about Tony matter. First, anabolic steroids and long-term supraphysiologic testosterone are associated with accelerated arterial calcification independent of the usual risk factors. His 1,159 was, in part, a signature of his pharmacology, not solely a signature of his cholesterol. Second, his exercise capacity was extraordinary and his nuclear study was a full-length, well-powered negative. Balanced ischemia is a threat when the stress test is short and inconclusive. It is a much smaller threat when the patient walks thirteen minutes and the images are clean.

Tony still owned every finished repair on that scan. His plan is aggressive lipid management, tightening of his testosterone protocol in coordination with the physician who prescribes it, and a rescan schedule that lets us watch how the number moves without treating him as if he were about to have an event tomorrow.

Frank and Tony had almost the same number and almost the same reading on their nuclear studies. Their catheterizations found nearly opposite anatomy. Tony’s story argued against the aggressive interpretation the number alone would have earned him.

Marcus, the zero, and the stent he needed anyway

Marcus is 42. Six feet, three hundred and ten pounds. Type 2 diabetes for four years, blood pressure 148/92 on two medications, LDL 113, triglycerides 240, waist circumference the size of a truck tire. Metabolic syndrome, by every classical definition. He had seen an advertisement on the radio for a $99 calcium score at a local imaging center, self-referred, paid out of pocket, and had the scan done on a Saturday morning. It came back zero. The report landed in his inbox with a one-line note that the study was normal.

He came to see me two weeks later because his zero had not made the other thing go away. For the past month he had been getting a pressure in his chest, mid-sternum, when he walked up the two flights of stairs to his office. It went away by the time he sat down at his desk. He had not told his wife. He had not told his primary care doctor. He told me because his cousin, who was his age and heavier than he was, had died of a heart attack four months earlier, and because the zero on his printout and the pressure in his chest did not fit together in a way he could reconcile alone.

He was right that they did not fit. He was wrong about which one to trust. If the calcium score alone had guided the plan, Marcus would have walked out of that imaging center reassured. He had none of the finished repairs the machine was built to detect. His arteries, from the scanner’s point of view, looked clean.

A zero does not cover soft plaque. The scanner cannot see it. Soft plaque is the wet stage, before the calcium arrives, when the cap is thin and the core is lipid-rich and the lesion is the kind most likely to rupture and cause a heart attack. In a 42-year-old with metabolic syndrome, an LDL of 113, and new exertional symptoms, the pretest probability of soft plaque is high, and a calcium score is the wrong tool to rule it out. In the Western Denmark Heart Registry, among symptomatic patients age 40 or younger who turned out to have obstructive coronary disease on CT angiography, 58 percent had a calcium score of zero. In a young symptomatic patient, soft plaque hides from the scanner often.

So Marcus got a stress test. It was positive. Anterior ischemia, exactly where the LAD supplies the heart. Catheterization showed a ninety percent narrowing in the mid-LAD, non-calcified plaque, the widow-maker distribution. He got a stent that afternoon.

Marcus’s zero was accurate. His arteries had not calcified any of the repair work yet. But the injury was there, the plaque was there, and the calcium score is not the test that finds it in a patient like him. The calcium score is a good test for asymptomatic risk stratification and a bad test for a symptomatic patient. No negative calcium score has ever bought a patient of mine an exit from a real symptom.

Marcus’s plan looks like every plan I write for a patient in his situation. Aggressive management of the metabolic syndrome — glucose, blood pressure, weight, sleep, inflammation, and lipids together, not one at a time. High-intensity statin. Dual antiplatelet therapy for the stent, aspirin and a P2Y12 inhibitor for the year the interventionalist and I agreed on. And a slower conversation, over the next year, about the deeper drivers of the injury that put a stent in the heart of a 42-year-old.

The zero was true. It just answered a question I had not fully asked.

Michael, 275, and a spreadsheet

Michael is 54. Real-estate appraiser, thin, runs three miles most Saturdays, LDL 168, HDL 51, triglycerides 118, blood pressure 132/84, hs-CRP 2.4, non-smoker, no diabetes. His primary care doctor calculated a 10-year PREVENT risk of 6.2 percent, which is intermediate, and the two of them decided a scan would settle the question. It came back at 275.

Michael has never taken a statin. He came in with a printout, a spreadsheet of his last five lipid panels, two weeks of home blood pressure readings taken the way I teach it — sit five minutes, rest and breathe, check three times in a row, log the lowest of the three — and a specific ask, which was to be talked out of medication. That home BP method, along with the rest of the natural-first approach to blood pressure, is written up in my book, Lower Your Blood Pressure, available on Kindle now with the paperback releasing October 20.

His 275 sits in the 100 to 299 band, and the 2026 ACC/AHA dyslipidemia guideline treats a score in that band as a marker of established atherosclerosis and moves the LDL target down accordingly. His percentile in the MESA reference tool is above the 75th for a 54-year-old man, which by itself crosses the same threshold. Two independent readings of his scan land in the same place.

Then I told him what the number meant in real terms. In the CAC Consortium follow-up, participants with a score in the 1 to 399 range carried roughly a twofold higher risk of coronary heart disease death compared with a zero after adjustment for the usual risk factors. That is Michael’s trajectory without treatment. The higher the risk you are starting from, the more a statin saves you. A 275 has more to gain from the same LDL reduction than a 25 does.

Michael pushed back where I expected him to. He runs, his weight is fine, and what he wanted to know was whether the running could carry the number the rest of the way. Lifestyle bends risk. It does not close a hundred-point LDL gap. The distance from 168 to where a 275 needs him to be is not a distance running has ever moved anyone.

We added the two together. He started a moderate-intensity statin, kept the running, added two days of resistance work, and we tightened the anti-inflammatory side of the plate. His three-month LDL came back at 71. His hs-CRP came down to 1.1. His real question was never about pills. His real question was whether the number meant he had a disease. It did. So we treated it.

A quick piece of history, because it changes the next patient

Before I introduce Ellen, I want to tell you where the calcium score came from, because the timing explains why the same number now means two different things.

In March of 1990, a Miami Beach cardiologist named Arthur Agatston and a radiologist named Warren Janowitz published a short paper in the Journal of the American College of Cardiology titled “Quantification of coronary artery calcium using ultrafast computed tomography”. The scanner they used was electron-beam CT, a machine fast enough to freeze the moving heart in an era when ordinary CT could not. Multidetector CT eventually replaced it, but the formula they proposed — area of each speck multiplied by a density factor, summed across all three coronary territories — survived intact. Every calcium score you have ever seen is still an Agatston score.

Lovastatin, the first statin the FDA approved, cleared in 1987. Agatston’s paper appeared in 1990. The scan that shows us plaque was invented into a world where the drug that stabilizes plaque had just barely arrived. For the first decade of calcium scoring, we were quantifying a disease process we could only partly treat. The aggressive treatment thresholds in the 2026 guideline are the product of thirty-six years of watching what happens to the number when a real drug meets a real repair. The scan is old technology. The interpretation is where the field has moved, and the interpretation is what the next patient’s story turns on.

Ellen, on treatment for fifteen years

Ellen is also 54. Similar build and roughly the same weekly mileage on the treadmill. Her first-ever calcium score came back at 275 too. She has been on atorvastatin 40 mg since her late thirties because her LDL ran above 220 in her twenties and a strong family history landed her under a lipid specialist’s care early. Her LDL on treatment is 62, her hs-CRP is 0.6, and her Lp(a) is 40 nmol/L.

Same number as Michael, same demographic, different plan.

The first thing I did was slow the room down, because a 275 on a treated patient looks like a treatment failure and it almost never is. I gave her the two sentences I give every long-term statin patient who gets a first-time positive scan.

One: your score is a count of the repairs your body finished. It is not a count of the repairs your body started.

Two: those repairs cured harder on a statin than they would have without one.

That is the statin paradox in one exchange. Statins pull lipid out of the soft core of a plaque and let the repair finish. Serial imaging studies show statin therapy associated with higher plaque density and lower low-attenuation and fibro-fatty plaque volume, and the Heinz Nixdorf Recall investigators documented the same accelerated calcification signal in statin-treated participants. The Agatston score, remember, weights each lesion by peak density. A patch that hardens without growing at all can score higher than the same patch would have scored while it was still soft. Ellen is not looking at fifteen years of runaway disease. She is looking at fifteen years of successful repair that the scanner can now see because it has cured to the density the machine was built to detect.

I do not tell Ellen the calcification itself is what protects her. I tell her what I can defend at the bedside. Her LDL is 62. Her hs-CRP is 0.6. Her Lp(a) at 40 nmol/L sits on the reassuring side of the risk cutoff. The number on her scan is a picture of repairs her body finished on a drug that helped them finish. Her clinical risk profile is what drives her plan, and by that profile she is exactly where I want a 54-year-old with her genetics to be.

Michael and Ellen have the same score and different risks. Michael’s 275 is a snapshot of untreated disease. Ellen’s is a snapshot of treated disease. The scanner does not distinguish between the two, so the physician has to.

For the untreated patient the same number means start. For the treated patient it means do not confuse the density of a successful repair with the failure of one.

Ellen kept her atorvastatin. Ellen’s plan is Ellen’s plan: an NMR lipoprofile to resolve the LDL into particle number and size, an eye on the Lp(a) where it already sat on the reassuring side of the cutoff, and continuation of the work that had brought her hs-CRP to 0.6 — anti-inflammatory eating, sleep, and stress management alongside the drug. Her plan was written in her thirties. Her scan confirmed it.

What none of the five scores said

Every one of those numbers was silent on the same four things, and I would rather say them plainly than let a reader discover them the hard way.

The score does not measure narrowing. It counts calcium. Blockage is a separate question with separate tests. Frank had a very high score and severe blockage. Tony had a very high score and almost no blockage. Same number, different angiograms.

The score does not measure soft plaque. It is blind to exactly the lesions most likely to rupture, which is why Marcus’s zero did not close the question in a symptomatic 42-year-old with metabolic syndrome. A zero from an asymptomatic 60-year-old with good numbers is a strong negative finding. A zero from a symptomatic 42-year-old with metabolic risk factors is the wrong test at the wrong time.

The score does not overrule symptoms. A zero in an asymptomatic person is powerful. A zero in a person with chest pain or exertional dyspnea is useful but not absolute. In a pooled analysis, a zero calcium score ruled out obstructive disease in 97 percent of patients with stable chest pain and 98 percent with acute chest pain. Those are strong numbers. They are not 100. Symptoms get evaluated on their own terms.

And the score does not tell you what caused it. The number counts the repairs. It says nothing about what kept injuring the wall in the first place. That answer comes from a blood draw and a conversation: LDL and apoB, Lp(a), blood pressure, fasting insulin and A1c, hs-CRP, sleep, and how much of the day is spent in a low-grade inflammatory state. The calcium score is where the workup starts, not where it ends. It tells me the fire has been burning. It does not tell me where the pilot light is.

Before you close this

The score counts the patches, not the leaks. It does not tell you whether the artery you are looking at is a Frank or a Tony, whether a zero is a Marcus, or whether a 275 is a Michael or an Ellen.

Five numbers, five plans, one test that was never designed to deliver a verdict.

What I am after in every one of these plans is the same three things. Calm the fire. Shrink the spackle bucket. And if there is a lot of sticky spackle, shrink the bucket a lot and the fire absolutely has to be out.

If you have a score, look up two things next to it: your absolute number and your percentile for your age and sex. A zero with symptoms does not answer the symptom. A first-time positive scan on a long-term statin is not a treatment failure until Ellen has been read again. And a score above 1,000 with a normal stress test is a set of results that only makes sense when you look at all of it together, the way I looked at Frank’s.

A few questions patients ask me. Can I lower my score? Not reliably; stabilizing what it represents is the goal. Should I rescan? Not for at least 3 to 5 years, and only if the result would change what we do. Does a high score mean I need a stress test? Not by itself, and not in the absence of symptoms.

If you are sitting with a folded printout in your pocket right now, the feeling you are having is the correct feeling, and it does not have to last. It usually takes about two visits for a frightening number to become a working number.

There is a younger healthier version inside of you and we are going to set them free together.

I will be here when the numbers come back.

Sameer Azhak, MD, FACC is a board-certified cardiologist with fellowship training in integrative medicine through the Andrew Weil Center. He writes The Integrative Cardiologist and its sister publication, The Menopause Heart. Reader mail reaches him at hello@theintegrativecardiologist.com.

This article is for educational purposes only and does not constitute medical advice or create a physician-patient relationship. Please consult your own physician before making changes to your treatment.

This publication is written by Sameer Azhak, MD, FACC, a board-certified cardiologist. It is provided for general educational and informational purposes only. It is not medical advice, is not a substitute for professional medical care, and does not create a physician-patient relationship between you and Dr. Azhak, Cordate Press, or Integrative Cardiology LLC.

Do not start, stop, delay, or change any treatment, medication, or supplement based on what you read here. Always consult your own physician about your specific medical situation. Dr. Azhak is licensed only in New Jersey; nothing here constitutes the practice of medicine in any other jurisdiction.

If you think you may be having a medical emergency, call 911 or go to the nearest emergency department immediately.

Please do not send protected health information or clinical questions by email or in comments — those channels are not HIPAA-secure. For the full, canonical disclaimer and privacy policy — including how subscriber data is handled by Substack and this publication — see drazhak.com/medical-disclaimer and drazhak.com/privacy.

Contact

For general questions (not clinical), use the contact form at drazhak.com. For patient care, please schedule with Heart & Vascular Associates at (973) 942-1141.

This page will be kept up to date. Last updated: August 2026.

I’m Dr. Sameer Azhak — a board-certified cardiologist and Fellow of the American College of Cardiology. For more than twenty years I’ve been the person patients come to after the cholesterol result, after the calcium score, after the sleepless night on Dr. Google. I trained conventionally at Seton Hall’s cardiovascular fellowship, and then, because I kept running into questions that cardiology alone couldn’t answer, I completed a fellowship in Integrative Medicine at the Andrew Weil Center for Integrative Medicine at the University of Arizona.

That combination is what this publication is about.

What “Preventative Cardiology, Integrated” actually means

I don’t call myself an integrative cardiologist — that’s not a real board, and I care about accuracy. What I do is combine two disciplines that usually live in separate hallways:

• Conventional cardiology: the trials, the labs, the imaging, the medications. The evidence base that has cut heart-attack mortality in half in my lifetime.

• Integrative medicine: nutrition, sleep, stress physiology, mind-body medicine, supplements when they’re indicated (and honesty when they aren’t).

Neither one, on its own, is enough. A statin without a plate that isn’t inflaming you every day is a rescue mission. A perfect Mediterranean diet without a look at your genetics (Lp(a), crp, homocysteine, ldl particle size and number, APO B) is a blind spot. This letter is where I bring both into the same conversation, in plain English, without the wellness hype and without the pharma-brochure minimalism.

What we’ll cover

Here’s the running docket:

• The numbers that matter. LDL (particle size and number), ApoB, Lp(a), hs-CRP, homocysteine, coronary calcium — what to ask for, when, and how to read the result.

• Food as cardiology. Anti-inflammatory eating, the real Mediterranean pattern (not the marketing version), and the shortlist of foods with the best evidence for your arteries.

• Blood pressure. What the number actually means, when to treat, and the lifestyle levers that move it the most.

• Cholesterol without the fear. Statins, Injectables, other pills, natural strategies, and when each is appropriate.

• Supplements. What has real data behind it, what doesn’t, and what to spend nothing on.

• The physiology of stress and sleep — and why cardiology has stopped ignoring them.

• How to read your own tests. Echocardiogram, stress test, CT calcium score, coronary CTA — how a cardiologist reads them, translated for you.

If you’ve been told “your numbers are fine” but something feels off, or “you should be on a statin” without anyone explaining why, or “just eat healthier” without anyone telling you what that means — this letter is for you.

What you won’t get here

• No fear-mongering. Cardiology can be sold as a horror movie. I refuse.

• No supplement affiliate links. If I recommend something, it’s because the evidence recommends it — not because someone paid me to say so.

• No replacement for your own doctor. This is education, not care. Nothing here creates a doctor-patient relationship. Bring what you learn here to your own physician.

A note on the sister publication

If you are a woman navigating perimenopause or menopause, your cardiovascular story has a chapter that gets its own letter: The Menopause Heart. Same author, same evidence-first tone, focused on the specific hormonal and vascular shifts that happen after 40. Cross-subscribe if you want both — I write them as companions.

What happens next

I’ll be publishing regularly — expect the first substantive article within the week. If you’re reading this because you already know me, thank you for being here from day one. If you found this letter through a search or a friend, welcome; the archive will grow quickly.

Two small favors:

1. Hit subscribe. It’s free. It’s how new posts find you.

2. Send this to one person whose heart you care about. That’s how this publication grows, and how better cardiology reaches more people.

Your heart is doing something remarkable right now — roughly 100,000 beats today, without a single conscious instruction from you. Let’s give it the care it deserves.

— Dr. Sameer Azhak

Board-certified cardiologist · Andrew Weil Center Integrative Medicine

Wayne, New Jersey

This post is for general educational purposes only. It is not medical advice, is not a substitute for care from your own physician, and does not create a physician-patient relationship. Do not start, stop, or change any treatment based on what you read here. If you think you may have a medical emergency, call 911 or go to the nearest emergency department. Full disclaimer at drazhak.com/medical-disclaimer.